Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you treat ER/PR + DCIS with no identified invasive component that has microscopic sentinel lymph node metastasis? Would you complete HER2 staining on original specimen?
DCIS with nodal metastasis in young fit patient.
Related Questions
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?